CD117 Antibody [CLDA117] | 33-916

CD117 Antibody [CLDA117] | 33-916 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human protein was used as the immunogen for this CD117 antibody.

Research Area: Cancer, Cell Cycle, Immunology, Neuroscience, Signal Transduction

Tested Application: IHC, IF

Application: Immunofluorescence: 0.5-1 ug/ml
IHC (FFPE) : 0.5-1 ug/ml for 30 minutes at RT (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD117 antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CLDA117

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Mast/stem cell growth factor receptor Kit, SCFR, Piebald trait protein, PBT, Proto-oncogene c-Kit, Tyrosine-protein kinase Kit, p145 c-kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, CD117, KIT, SCFR

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CD117, or p145kit, is found on a wide variety of tumor cells including follicular and papillary carcinoma of thyroid, adenocarcinomas from endometrium, lung, ovary, pancreas, and breast as well as malignant melanoma, endodermal sinus tumor, and small cell carcinoma. CD117 antibody has been particularly useful in differentiating gastrointestinal stromal tumors from Kaposi���s sarcoma, tumors of smooth muscle origin, fibromatosis, and neural tumors of the GI tract.